HOPA is actively working on behalf of the hematology/oncology pharmacists and patients to maintain quality and safety in cancer care. Following are recent initiatives that HOPA has participated in on the association's behalf:
House Energy and Commerce Committee Call for Changes in 340B Discount Drug Program
Republicans on the House Energy and Commerce Committee released a report that calls for an overhaul of the 340B discount drug program. Although the program has saved 340B hospitals about $6 billion in 2015, some GOP lawmakers have criticized the program due to lack of government oversight. The committee has recommended changes to the program, including defining the program’s purpose and adding reporting requirements for hospitals. Read the full 77-page report here.
FDA Releases Final Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product.
GOP Leaders Issue Letter Cautioning Agencies Not to Finalize Rules. Of interest to HOPA is the Medicare Part B Rule which is still in flux.
President's Cancer Panel Releases Latest Report, Improving Cancer-Related Outcomes with Connected Health